Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma
Abstract
Reduced‐intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo‐HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular conditioning regimen. We analyzed 492 adult patients undergoing human leucocyte antigen (HLA)‐matched sibling or unrelated donor allo‐HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan (Flu/Bu), fludarabine/melphalan (Flu/Mel140) or fludarabine/cyclophosphamide (Flu/Cy). Multivariable regression analysis was performed using a significance level of P = 0·54), relapse/progression (P = 0·02) or progression‐free survival (PFS) (P = 0·14). Flu/Cy conditioning was associated with decreased risk of mortality in the first 11 months after allo‐HCT (HR = 0·28; 95% CI = 0·10–0·73; P = 0·009), but beyond 11 months post allo‐HCT it was associated with a significantly higher risk of mortality, (HR = 2·46; 95% CI = 0·1.32–4·61; P = 0·005). Four‐year adjusted overall survival (OS) was similar across regimens at 62% for Flu/Bu, 59% for Flu/Mel140 and 55% for Flu/Cy (P = 0·64), respectively. These data confirm the choice of RIC for allo‐HCT in HL does not influence risk of relapse, NRM or PFS. Although no OS benefit was seen between Flu/Bu and Flu/Mel 140; Flu/Cy was associated with a significantly higher risk of mortality beyond 11 months from allo‐HCT (possibly due to late NRM events).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 21, 2020
- Source ID
- 10.1111/bjh.16664
Entities
People
- Alberto Mussetti
- Amir Steinberg
- Anna Sureda
- Basem William
- Carlos Litovich
- Jan Cerny
- Jennifer Kanakry
- Kwang W. Ahn
- Manoj Khanal
- Marjolein Van Der Poel
- Matthew Mei
- Mehdi Hamadani
- Mitchell S Cairo
- Mohamed A Kharfan-Dabaja
- Nelli Bejanyan
- Nilanjan Ghosh
- Parastoo B. Dahi
- Richard F. Olsson
- Sachiko Seo
- Sairah Ahmed
- Saurabh Chhabra
- Sunita Nathan
- Timothy S. Fenske
- Umar Farooq
Organizations
- Bellvitge Biomedical Research Institute
- Dokkyo Medical University
- H. Lee Moffitt Cancer Center & Research Institute
- Karolinska Institutet
- Levine Cancer Institute
- Maastricht University
- Medical College of Wisconsin
- Memorial Sloan Kettering Cancer Center
- Mount Sinai Hospital
- National Cancer Institute
- New York Medical College
- Office of Naval Research
- Ohio State University
- Rush University Medical Center
- University of Barcelona
- University of Iowa
- University of Texas at Austin
- Uppsala University